Although there are some experimental skin patches where GLP-1 agonist medicines like semaglutide are used as active ingredients, these are still under trial and not yet approved for use
Higher doses achieved the most pronounced reductions without major safety concerns
Who May Qualify for a GLP-1 Lawsuit You may qualify for a GLP-1 injury claim if you meet the following criteria: Medication: Use of a brand-name GLP-1 drug Ozempic, Wegovy, Mounjaro, Trulicity, or Rybelsus Duration: Used the medication for at least 23 months Purpose: Prescribed for weight loss or diabetes Injury: Gastroparesis a condition characterized by partial or complete paralysis of the stomach, leading to delayed gastric emptying Severe intestinal obstruction (ileus) a disruption of normal bowel function causing significant blockage of the intestines Gallbladder disease resulting in cholecystectomy (surgical removal of the gallbladder) prior to 2022 Treatment: Emergency room or hospital visit required Common GLP-1 Side Effects and Injuries While many patients tolerate GLP-1 receptor agonists well, others experience debilitating side effects such as chronic nausea, vomiting, abdominal pain, dehydration, and severe gastrointestinal distress
Source: Polaris Market Research Analysis Key Players & Competitive Analysis Report The GLP-1 sector is witnesses competition due to revenue growth opportunities in both developed and emerging markets
